NCT04920747View on ClinicalTrials.gov

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions

HER2-positive Gastric CancerMetastatic CancerDocetaxelTrastuzumab

Interventions

DRUG

Taxane

docetaxel or paclitaxel

Trial Locations (1)

25030

CHU Besancon, Besançon

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT04920747 - Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients | Biotech Hunter | Biotech Hunter